Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
News|Articles|June 8, 2015
Malvern Showcases Analytical Tools for Drug Discovery and Development
Author(s)Pharmaceutical Technology Editors
At this year’s ACHEMA, Malvern brings to the exhibition floor, its expertise and tools for measuring particle size and shape, zeta potential, molecular weight, and rheological properties for the characterization of dispersed systems.
Malvern Instruments’ products provide information to drive drug discovery and development. At this year’s ACHEMA, the company brings to the exhibition floor, its expertise and tools for measuring particle size and shape, zeta potential, molecular weight, and rheological properties for the characterization of dispersed systems.
The Malvern MicroCal PEAQ-ITC and PEAQ-ITC Automated systems, which were launched earlier this year, offer robust performance and enhanced functionality for the study of biomolecular interactions.
Malvern is also showcasing its new Viscosizer TD for automated ultra low volume particle and molecular sizing via Taylor dispersion analysis.
OMNISEC, a fully integrated, easy-to-use, multi-detector GPC/SEC system delivers high sensitivity molecular weight, molecular weight distribution, size and structure measurements for proteins as well as for natural and synthetic polymers.
The Mastersizer 3000 is Malvern’s flagship laser diffraction particle size analyzer, which features Hydro Sight, a state-of-the-art imaging accessory that makes it quicker and easier to develop, apply, and troubleshoot particle sizing methods.
Other products on display include the Morphologi G3-ID, used for the measurement of particle size, shape, and chemical identity with Raman spectroscopy; the Kinexus range of rotational rheometers; and the Zetasizer Nano, for nanoparticle, colloid, and protein size zeta potential measurements and molecular characterization.
Source: Malvern, Hall 4.1, Stand D59
Related to this article
The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Subathra Ramamoorthy, Veranova, on when to escalate to structural elucidation and pair orthogonal techniques when characterizing an impurity.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, discusses the limitations of current preclinical testing approaches and how new approach methodologies can strengthen drug development.